^†In the CYTO-PV study of 365 adult patients with PV treated with PBT, HU, or both, patients were randomized to 1 of 2 groups—either the low-Hct group (n = 182; with more intensive therapy to maintain a target Hct level <45^%) or the high-Hct group (n = 183; with less intensive therapy to maintain a target Hct level of 45^% to 50^%). Baseline characteristics were balanced between the groups. Approximately 50^% of patients had received an initial diagnosis of PV within 2 years prior to randomization. 67.1^% of patients (n = 245) were at high risk because of age ≥65 years or previous thrombosis. The composite primary endpoint was the time until cardiovascular death or major thrombosis.²

^†In the CYTO-PV study of 365 adult patients with PV treated with PBT, HU, or both, patients were randomized to 1 of 2 groups—either the low-Hct group (n = 182; with more intensive therapy to maintain a target Hct level <45^%) or the high-Hct group (n = 183; with less intensive therapy to maintain a target Hct level of 45^% to 50^%). Baseline characteristics were balanced between the groups. Approximately 50^% of patients had received an initial diagnosis of PV within 2 years prior to randomization. 67.1^% of patients (n = 245) were at high risk because of age ≥65 years or previous thrombosis. The composite primary endpoint was the time until cardiovascular death or major thrombosis.²

^§REVEAL was a prospective, observational study of 2510 adult patients with PV in the United States, sponsored by Incyte. Patients were enrolled over an approximate 2-year period (July 2014 to August 2016). This analysis included all enrolled patients and evaluated characteristics of deceased patients, survival by risk, and causes of death over the course of the study. A total of 244 patients died during the study, with 190 having elevated Hct values and WBC counts in the 6 months before death, and 175 having a known cause of death. Among the 244 patients who died during the study, 82^% (n = 200) were categorized as high risk at diagnosis, primarily due to age ≥60 years only (65^%; n = 159).^4,5